Avestar Capital LLC Has $575,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Avestar Capital LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 15.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,945 shares of the company’s stock after acquiring an additional 386 shares during the quarter. Avestar Capital LLC’s holdings in Zoetis were worth $575,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the 3rd quarter valued at $33,000. Quarry LP increased its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Finally, LRI Investments LLC bought a new position in Zoetis during the first quarter worth about $43,000. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 1.7 %

ZTS opened at $175.70 on Wednesday. The company has a market cap of $79.27 billion, a P/E ratio of 33.03, a PEG ratio of 2.74 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average is $184.91 and its 200-day moving average is $180.84. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $1.36 earnings per share. Equities research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.